Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 15 Neoplasms 10 Carcinoma, Renal Cell 8 Carcinoma, Hepatocellular 8 Melanoma 7 Carcinoma, Non-Small-Cell Lung 7 Endometrial Neoplasms 6 Thyroid Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 4 Recurrence 4 Thyroid Cancer, Papillary 3 Stomach Neoplasms 3 Neuroendocrine Tumors 3 Colorectal Neoplasms 3 Adenocarcinoma, Follicular 3 Ovarian Neoplasms 2 Osteosarcoma 2 Neoplasm Metastasis 2 Lymphoma 2 Lung Neoplasms 2 Glioma 2 Carcinoma, Transitional Cell 2 Carcinoma 2 Biliary Tract Neoplasms 2 Uveal Melanoma 1 Triple Negative Breast Neoplasms 1 Thyroid cancer, medullary 1 Thyroid cancer, Hurthle cell 1 Thyroid Diseases 1 Thyroid Carcinoma, Anaplastic 1

Interventions

Doxorubicin 33 Ifosfamide 23 Gemcitabine 19 pazopanib 18 Cyclophosphamide 16 Radiotherapy 15 pembrolizumab 13 Filgrastim 12 Docetaxel 12 Bevacizumab 10 Vincristine 9 Sirolimus 9 Irinotecan 9 Etoposide 9 olaratumab 7 eribulin 7 Sorafenib 7 Radiation 7 temsirolimus 6 Temozolomide 6 Mesna 6 Magnetic Resonance Spectroscopy 6 Cisplatin 6 tazemetostat 5 cixutumumab 5 Trabectedin 5 Radiosurgery 5 Nivolumab 5 Ipilimumab 5 Granulocyte Colony-Stimulating Factor 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Sarcoma × lenvatinib × Clear all

NCT03526679 2025-12-05

LEADER

National Taiwan University Hospital

Phase 1/2 Completed

30 enrolled 9 charts

Leiomyosarcoma, Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡